A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
Atavistik Bio, Inc
K36 Therapeutics, Inc.
Cedars-Sinai Medical Center
AstraZeneca
Inhibrx Biosciences, Inc
Pathos AI, Inc.
University of Washington
Marengo Therapeutics, Inc.
Novartis
Advanced Accelerator Applications
Revolution Medicines, Inc.
Endocyte